Teva Granted ANDA Approval for Eisai’s Aciphex
This article was originally published in The Pink Sheet Daily
Executive Summary
Patent litigation could impact possible launch of proton pump inhibitor.
You may also be interested in...
Aciphex Patent Case Will Continue On Enforceability Grounds
Eisai wins a summary judgment against Dr. Reddy’s and Teva on the validity of its rabeprazole patent but must go to trial on enforceability claims.
Actelion CEO Jean-Paul Clozel: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
CEO Clozel discusses the firm’s renin inhibitor program in the face of Novartis’ Tekturna, alliances with Merck and Roche and its business strategy going forward.
Actelion CEO Jean-Paul Clozel: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
Exec discusses the firm’s pulmonary arterial hypertension drug Tracleer and other endothelin receptor antagonists in Actelion’s pipeline.